"Nobel Prize in Medicine" revealed a number of "first" products on the list

Today, the American Galien Foundation announced the winners of the 2020 Prix Galien Awards.
, known as the "Nobel Prize in Medicine", is recognized as the highest honor in the pharmaceutical and biomedical industries for outstanding scientific innovations to improve human health.
is the 50th anniversary of the Galen Awards, and since its inception in 1970, 268 biopharmaceutical products have been awarded, covering 18 therapeutic areas.
Photo Source: The Galen Foundation's official Galen Award was chosen by a jury of Nobel laureates, including best pharmaceutical product, best biotechnology product and best medical technology.
are all FDA-approved products that have been approved for listing in the last five years and have the potential to have a significant impact on human health.
this year, the Galen Foundation also launched the Best Digital Health Products Award for the first time, recognizing the indispensable role of digital health solutions in healthcare systems.
This year's winners are: Best Drug Award: Pretomanid, a new molecular entity developed by the non-profit TB Drug Development Alliance (TB Alliance) to treat specific highly drug-resistant tuberculosis (TB) patients.
, which was approved by the FDA in 2019, is the third new drug against tuberculosis approved by the FDA in nearly 40 years and the first to be developed and marketed by a nonprofit.
multidrug-resistant TB (multidrug-resistant TB) and extensively drug-resistant TB (extensive drug-resistant TB) have become major threats to human health due to increasing bacterial resistance.
, according to the World Health Organization, there were 490,000 new multidrring-resistant TB patients worldwide in 2016, a small percentage of whom were widely drug-resistant TB patients.
patients are insatiable or resistant to multiple therapies, so treatment options are very limited.
most patients with extensively drug-resistant TB may need to be treated with up to eight antibiotics for up to 18 months or more.
WHO estimates that the success rate of treatment for patients with extensive drug-resistant TB is about 34%.
pretomanid molecular structure (Photo: Fvasconcellos 18:28, 3 June 2007 (UTC) in a key clinical trial, 109 patients with extensive drug resistance TB, and patients with multiple resistance to existing therapies that are insensitive or unresponsive, were treated with a combination of Pretomanid and bedaquiline and linezolid.
trial results showed that after 6 months of treatment, the success rate of this combination therapy was 89%, significantly higher than the historical success rate of treating patients with extensive drug resistance TB.
Best Medical Technology Award: MitraClip by catheter di tip valve repair system, Abbott MitraClip is the world's first transductive di tip valve repair (TMVr) treatment system, can provide treatment options for some primary or secondary secondary di tip valve closure incomplete patients, who would otherwise not be able to receive treatment.
MitraClip has been used worldwide to treat more than 80,000 patients.
Image Source: Abbott's Best Biotechnology Product Award: Tegsedi, Akcea Therapeutics and Ionis Pharmaceuticals Onpattro, Alnylam Pharmaceuticals Vyndaqel, Pfizer genetic thyroxine protein amyloid degeneration (hATTR) is a deadly carried genetic disease caused by abnormal folding of thyroxine protein (TTR) in the patient's body, causing amyloid TTR to be deposited in various tissues and organs of the body.
TTR deposits include peripheral nerves, heart, intestines, eyes, kidneys, central nervous system, thyroid gland and bone marrow.
the deposition of TTR in these tissues and organs creates a variety of sensory, motor and plant-based abnormalities that eventually lead to the patient's death within 3-5 years of the on-the-appearance of symptoms.
estimated that there are about 50,000 hight ATTR patients in the world.
three products that have won awards this year treat the disease from different perspectives.
Tegsedi is an antonymic oligonucleotide drug that inhibits human TTR synthesis and, by combining with mRNA encoded by TTR proteins, can lead to the degradation of mRNA, thereby reducing the level of TTR proteins (wild and mutant).
it is a weekly subsuppassion injection that patients can self-inject at home.
Onpattro, developed by Allenylam, is an RNAi therapy that targets transthyretin (TTR), which works by silently involving a portion of the disease-caused mRNA.
Onpattro, which wraps siRNAs in lipid nanoparticles, delivers the drug directly to the liver in infusion therapy, and by combining with mRNA that encodes abnormal TTR to prevent the production of TTR, Onpattro can help reduce the accumulation of amyloid deposits in the surrounding nerves, improve symptoms, and help patients better control the condition.
is also the first RNAi therapy approved by the FDA.
Vyndaqel, developed by Pfizer, is an oral TTR stabilizer that stabilizes the tetr's tetum form by binding to the specificity of TTR, thus delaying the production of amyloid deposition.
approved by the FDA for the treatment of cardiomyopathy caused by amyloid degeneration of wild-type or hereditary thyroxine protein.
best digital health products: Somryst, developed by Pears Pears Pear Therapeutics, is the first FDA-approved prescription digital therapy (PDT) for insomnia.
Somryst aims to provide patients with individualized neuro-behavioral interventions, mainly using algorithm-driven cognitive behavioral therapy (CBTi) to improve insomnia symptoms and provide first-line treatment for patients.
addition, Somryst provides a board used by clinicians that allows healthcare providers to track patient treatment and disease progress.
clinician's indicator board can display information about a patient's use of Somryst, including insomnia severity index (ISI), patient health questionnaire (PHQ-8), and sleep indicators from a nighttime sleep diary.
references: the Galien Foundation. Retrieved October 29, 2020, from The Galien Foundation Introduces 2020 Prix Galien USA Nominees in "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" Categories. Retrieved October 29, 2020, from The Galien Foundation Debuts 2020 Prix Galien Nominees in New Category for "Best Digital Health Product." Retrieved October 29, 2020, from MitraClip. Retrieved October 29, 2020, from . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .